Welcome to our dedicated page for Novavax news (Ticker: NVAX), a resource for investors and traders seeking the latest updates and insights on Novavax stock.
Novavax, Inc. (NASDAQ: NVAX) is a biotechnology company focused on vaccines, using a platform that combines protein-based nanoparticles with its proprietary Matrix-M® adjuvant. News about Novavax often centers on its COVID-19 vaccine Nuvaxovid™/Nuvaxovid®, its broader infectious disease pipeline, and the progress of key partnerships and collaborations.
Recent announcements highlight Novavax’s collaboration and license agreement with Sanofi, under which Sanofi has taken on lead commercial and regulatory responsibilities for Nuvaxovid in selected markets. News items cover marketing authorization transfers in the European Union and United States, milestone payments to Novavax, and Sanofi’s clinical data on combination vaccine candidates that incorporate Nuvaxovid and Matrix-M. Updates also describe regulatory approvals in markets such as Japan through partner Takeda, triggering additional milestone payments and royalty opportunities.
Investors following NVAX news will see regular coverage of quarterly financial results, revenue composition from product sales, supply sales and licensing and royalty streams, as well as information on Novavax’s site consolidation and cost footprint in Maryland. The company’s communications also describe early-stage research on vaccine candidates for shingles, Clostridioides difficile colitis and respiratory syncytial virus combinations, and the use of Matrix-M in the R21/Matrix-M malaria vaccine developed with Serum Institute of India and Oxford University.
This page aggregates press releases, conference participation announcements, regulatory updates and other material events related to Novavax. Readers can use it to monitor developments in the company’s vaccine programs, partnership milestones, capital structure transactions and strategic transformation as disclosed in public statements.
Novavax (Nasdaq: NVAX) completed transfer of the EU marketing authorization for its COVID-19 vaccine Nuvaxovid to Sanofi on Oct 7, 2025, triggering a $25 million milestone payment to Novavax and advancing the companies' collaboration and license agreement.
Novavax remains eligible for additional milestones and tiered royalties including a $25 million U.S. transfer milestone, a $75 million technology-transfer milestone, up to $350 million for certain Sanofi combination-product milestones, up to $200 million for the first four Matrix-M products, and ongoing royalties on sales.
Novavax (Nasdaq: NVAX) has expanded its collaboration with Sanofi through an amended license agreement for Novavax's Matrix-M® adjuvant. The amendment allows Sanofi to use Matrix-M in their pandemic influenza vaccine candidate program through Phase 2 development, supported by BARDA funding.
Under the original agreement terms, Novavax can receive up to $200 million for the first four Sanofi products using Matrix-M, and up to $210 million in milestone payments for each subsequent product, plus ongoing royalties. The companies will negotiate additional terms if Sanofi proceeds to Phase 3 development.
Novavax (NASDAQ:NVAX) has announced that its COVID-19 vaccine Nuvaxovid® has received regulatory approval in Japan, triggering a milestone payment from Takeda. The vaccine is approved for initial immunization in ages 6+ and booster shots for ages 12+, specifically formulated to target the SARS-CoV-2 Omicron LP.8.1 variant.
The approval grants Novavax access to Japan's healthcare market, the world's third-largest. Under the collaboration agreement with Takeda, Novavax will receive undisclosed milestone payments and royalties on net sales, with a portion of the milestone payment applicable to future royalty payments.
Novavax (Nasdaq: NVAX) announced its participation in the upcoming Cantor Global Healthcare Conference. The company will engage in a fireside chat on Thursday, September 4, 2025, at 10:20 a.m. ET in New York, NY.
Investors can access the presentation through a webcast on the Events & Presentations page at ir.novavax.com, with replay availability for 30 days following the event.
Novavax (NASDAQ:NVAX) has received FDA approval for its Nuvaxovid™ 2025-2026 Formula, the only protein-based, non-mRNA COVID-19 vaccine available in the U.S. The vaccine is approved for adults aged 65 and older and individuals 12-64 years with high-risk conditions.
Clinical and preclinical data demonstrate the vaccine's effectiveness against currently circulating JN.1 lineage strains, including NB.1.8.1, LP.8.1, XFG, XFC, LF.7, and XEC. Sanofi will lead commercialization efforts, with Novavax receiving tiered royalties from vaccine sales.
The vaccine's safety profile includes warnings for potential side effects such as myocarditis, pericarditis, and common reactions like injection site tenderness and fatigue.
Novavax (NASDAQ:NVAX) has announced a significant debt refinancing transaction involving its convertible notes. The company will issue $225 million of 4.625% Convertible Senior Notes due 2031, comprising $175.3 million in exchange for existing 2027 Notes and $49.7 million in new funding.
The 2031 Notes will have an initial conversion price of $11.14 per share, representing a 27.5% premium over the August 20, 2025 closing price. After the transaction's completion, expected around August 27, 2025, $26.5 million of the 2027 Notes will remain outstanding, while the new 2031 Notes will total $225 million.
Novavax (NASDAQ:NVAX) reported second quarter 2025 financial results with total revenue of $239 million, down 42% from $415 million in Q2 2024. Key highlights include FDA BLA approval for Nuvaxovid™, triggering a $175 million milestone payment from Sanofi, and completion of the U.S. commercial leadership transition to Sanofi for the 2025-2026 COVID-19 vaccination season.
The company reported net income of $107 million and ended the quarter with $628 million in cash. Phase 3 trial data for COVID-19-Influenza-Combination and stand-alone influenza vaccine candidates showed robust immune responses. Novavax updated its Full Year 2025 guidance, expecting Adjusted Total Revenue between $1,000-$1,050 million and combined R&D and SG&A expenses of $495-$545 million.
Novavax (Nasdaq: NVAX) has scheduled its second quarter 2025 financial results and operational highlights conference call for August 6, 2025, at 8:30 a.m. ET. The company will host a conference call with both domestic and international dial-in options, and participants can register online for automated callback access.
A replay of the conference call will be available from 11:30 a.m. ET on August 6 until August 13, 2025. The webcast replay will remain accessible on the company's investor relations website until September 5, 2025.
Novavax (NASDAQ:NVAX) has announced promising preclinical data for its H5N1 avian pandemic influenza vaccine candidate, published in Nature Communications. The vaccine, utilizing Novavax's recombinant protein-based nanoparticle technology and Matrix-M® adjuvant, demonstrated strong immune responses in nonhuman primates through both intranasal and intramuscular administration.
The study revealed that a single dose induced significant neutralizing antibody responses (intranasal: 1:54; intramuscular: 1:1,160), exceeding the protective threshold of 1:40 titer. The vaccine showed potential effectiveness against forward-drift variants of currently circulating H5N1 strains. Novavax plans to pursue funding, partnership, and licensing opportunities for this vaccine candidate as part of its corporate growth strategy.